APR 05, 2016 7:06 AM PDT

For Some Osteoporosis, Taking Medications May Be a Mistake

WRITTEN BY: Xuan Pham
A recent study found that treating osteoporosis brought on by hyperparathyroidism with conventional drugs could actually do more harm than help. Instead of taking medicines that seemingly strengthen bones but that are linked to more fractures, the researchers say surgery to remove the overactive parathyroid gland is a more effective alternative.
 
Osteoporosis refers to the loss of calcium from bones, leading to thin and brittle bones that are prone to fracture. The condition is commonly known occur as the body ages normally, but it also occurs as a result of hyperparathyroidism – that is, overactive parathyroid glands. Nearly 400,000 Americans suffer from osteoporosis brought on by their hyperparathyroidism. "Hip fractures, in particular, are associated with significant rates of mortality, disability and loss of independence," said Michael Yeh, an associate professor of surgery and medicine, and first study author.
 
Left: normal bones. Right: bones with osteoporosis

Calcium, the main component that give bones its strength and toughness, is regulated by the parathyroid hormone (PTH), which are released from the parathyroid glands, located in the neck. Normal functioning parathyroids produce PTH when the body is low on calcium, and stops PTH production when calcium levels are sufficient. In hyperparathyroidism, too much hormones over-stimulate the release of calcium from bones into the bloodstream and the subsequent reabsorption by the kidney and intestines. As a result, kidney stones accumulate more in patients with hyperparathyroidism. Moreover, bones quickly lose their calcium reserve and become thin and brittle, prone to fracture.
 
To combat bone loss in hyperparathyroidism, doctors routinely prescribe bisphosphonates, medicines that reduce calcium loss and strengthen bones. These include alendronate (trade name Fosamax) and ibandronate (trade name Boniva). Strangely, though X-rays show increased bone densities from these drugs, doctors didn’t see a corresponding reduction in bone fractures.
 
"Before this study, there was no data that compared parathyroid surgery with prescribing medication on the risk for fractures in people with hyperparathyroidism,” said Yeh. So he and his team set to describe such comparison, using data from over 6,000 people diagnosed with hyperthyroidism over a 10-year span.
 
They found that patients who had surgery to remove the affected parathyroid glands showed the least amount of hip fractures (20 per 1,000 people). People who received no treatment at all for their hyperparathyroidism had the next highest amount of fractures (56 per 1,000 people). The “startling” finding was in the next group: those who were treated bisphosphonates had the highest amount of hip fractures (86 per 1,000 people), which suggests taking the medicine has worse outcomes than if nothing was done at all! The team found the trend persisted when they tallied up all bone fractures of all types.
 
Why would medications that seemingly strengthen bones, as observed in X-rays, show higher incidences of bone fractures? The researchers were also surprised at this finding and can only speculate to the answer. "The drugs make the bones look dense on scans, but that is deceptive," Yeh said. "We must presume there is a defect in the quality of the bone. But we don't know why."
 
"Regardless, we were unable to demonstrate any benefit associated with this class of drugs, which have been around and routinely prescribed for more than 20 years," Yeh concluded. "These findings should make bisphosphonates less attractive as an alternative to parathyroid surgery in patients with primary hyperparathyroidism."
 

Additional source: UCLA press release 
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
OCT 27, 2020
Clinical & Molecular DX
A Super Sensitive Alzheimer's Test Powered by Nanozymes
OCT 27, 2020
A Super Sensitive Alzheimer's Test Powered by Nanozymes
  Simple tasks are now uphill struggles, social situations aren’t fun, and the car keys are missing again. By ...
NOV 24, 2020
Clinical & Molecular DX
Young Inventor Creates Award-winning At-home Cancer Diagnostic
NOV 24, 2020
Young Inventor Creates Award-winning At-home Cancer Diagnostic
Getting a breast cancer diagnosis often means having to endure multiple tests, including some painful and invasive proce ...
DEC 08, 2020
Clinical & Molecular DX
"Honey, I Shrunk the PCR."
DEC 08, 2020
"Honey, I Shrunk the PCR."
In the 1530s, hundreds of years before microscopes and Petri dishes, an Italian physician called Girolamo Fracastoro wro ...
DEC 16, 2020
Clinical & Molecular DX
Gene Marker PACS a Punch for Cervical Cancer Treatments
DEC 16, 2020
Gene Marker PACS a Punch for Cervical Cancer Treatments
In cervical cancer, mutations in healthy cells cause cells to grow and multiply uncontrollably, invading surrounding tis ...
FEB 04, 2021
Clinical & Molecular DX
Neurological and Psychiatric Aftershocks of the Pandemic
FEB 04, 2021
Neurological and Psychiatric Aftershocks of the Pandemic
One in eight COVID-19 survivors have received a diagnosis of a neurological or psychiatric condition in the year followi ...
FEB 25, 2021
Clinical & Molecular DX
A Better Way to Triage COVID Patients
FEB 25, 2021
A Better Way to Triage COVID Patients
Australian researchers have developed a COVID-19 triaging tool that serves as a crystal ball for healthcare workers. Onc ...
Loading Comments...